Sign In
Buy WGS
$53.02
-0.110 (-0.207%)
At Close: Jun 03, 2026
-- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases commercial footprint and focus on acceleratin
GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
07:00am, Thursday, 06'th Jun 2024
GeneDx Holdings Corp. focuses on delivering precise medical diagnostic outcomes through its genomic expertise and rare disease dataset. Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) a
GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
07:00am, Wednesday, 05'th Jun 2024
STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access
Insider Buying Heats Up at Fracker, Aircraft and Boat Makers, and More
09:15am, Sunday, 02'nd Jun 2024
With the earnings-reporting season having all but concluded, the windows for making insider purchases are generally open.
GeneDx to Participate in Upcoming Investor Conferences
04:05pm, Wednesday, 22'nd May 2024
STAMFORD, Conn., May 22, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participa
GeneDx Holdings Corp. (WGS) Q1 2024 Earnings Call Transcript
09:42pm, Monday, 29'th Apr 2024
GeneDx Holdings Corp. (NASDAQ:WGS ) Q1 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief
GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates
06:50pm, Monday, 29'th Apr 2024
GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $2.82 per share a year ago.
GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
04:05pm, Monday, 29'th Apr 2024
Reported first quarter 2024 revenue from continuing operations 1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins 2 from con
GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset
08:30am, Tuesday, 23'rd Apr 2024
The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine The Company will also participate in a
GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
04:05pm, Thursday, 04'th Apr 2024
Management will host a conference call on Monday, April 29, 2024 to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.
Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher
10:56am, Thursday, 21'st Mar 2024
GENEDX HOLDINGS (WGS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among
Wipro Enters into Agreement with Desjardins to Modernize Consumer Banking Services Using its NetOxygen Platform
07:12pm, Friday, 15'th Mar 2024
The solution will improve Desjardins’ consumer lending and credit card business TORONTO & BENGALURU, India–(BUSINESS WIRE)–$WIPRO #AdvisoryServices–Wipro Limited (NYSE: WIT, BSE: 507685, NSE:
STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the
GeneDx to Participate in 44th Annual Cowen Health Care Conference
04:05pm, Monday, 26'th Feb 2024
STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management
GeneDx Holdings Corp. (WGS) Q4 2023 Earnings Call Transcript
06:20pm, Tuesday, 20'th Feb 2024
GeneDx Holdings Corp. (WGS) Q4 2023 Earnings Call Transcript
